P53 gene mutations among patients involved with breast cancer: types of detection

Abstract

A significant transcription factor that is involved in the regulation of numerous cellular functions is the tumor suppressor p53. In disease, p53 weakens cell expansion in light of different boosts, including DNA harm, supplement hardship, hypoxia, and hyperproliferative signs, along these lines forestalling growth arrangement. It was detailed that the proficiency of Microarray and ABI 310 framework in distinguishing proof a wide range of p53 quality transformations. Microarray and ABI 310 analysis were used in this study to find p53 gene mutations in archived breast cancer tissues. Breast tissues from cancer patients who had been diagnosed with breast cancer were collected for this purpose and paraffin-embedded after being formalin-fixed. DNA was removed by the Microdissection technique and was cleaned with Microcon 50 channels (Millipore) prior to performing PCR. Twelve of the samples that were analyzed had ABI 310 system mutations in the p53 gene, the genomic DNA was acquired from micro-dissected tests without laser. The ABI 310 system identified p53 gene mutations in three of the nine ESCC specimens from patients who were examined by microarray. In laser-miniature analyzed examples changes were distinguished by ABI 310 framework. The extricated DNA obtained from laser miniature took apart examples was deficient for the evaluation of p53 quality changes with Microarray. It was resolved that Microarray was reliant upon how much tissues were utilized in DNA extraction. The resulting data of this study showed that selecting the appropriate method for extracting DNA from test samples in order to evaluate the p53 gene mutation is crucial. The ABI 310 system and Microarray were able to detect p53 gene mutations (for exons 5-8) with an efficiency of 99.6% and 27%, respectively. Consequently, involving new tissues for Microarray analysis is suggested. In conclusion, the application of Microarray to identify mutation for p53 gene, in breast cancer tissues, will be necessary for central hospitals, where fresh tissue samples are available easily.